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TO THE EDITOR
Receptor of activator NF-κB ligand
(RANKL) and RANK were originally
identiﬁed as a cytokine and its receptor,
respectively, which regulate the function
of dendritic cells (DCs) (Anderson et al.,
1997; Wong et al., 1997). RANK/RANKL
also have a role in osteoclast diffe-
rentiation (Yasuda et al., 1998). RANKL
signaling promotes the survival of
conventional DCs and ensures T-cell pri-
ming and activation, thereby enhancing
the acquired immune response. On the
other hand, in the skin, RANKL-treated
DCs maintain the number of CD4+
CD25+ regulatory T cells (Tregs) to sup-
press the immune response against self-
antigens, food, and commensal ﬂora. In
addition, UV irradiation upregulates the
expression of RANKL in keratinocytes,
which stimulates RANK on Langerhans
cells, leading to UV-induced cutaneous
immunosuppression (Loser et al.,
2006). In the accompanying report
(Kambayashi et al. 2015) we showed
that in extramammary Paget’s disease
(EMPD), 60% of the RANK+ cells are
CD163+ macrophages and a substantial
amount of soluble RANKL (sRANKL) is
released in the lesional skin of EMPD.
We therefore hypothesized that this
RANKL might have an effect on
CD163+RANK+ M2 macrophages.
To explore the potential effects of
sRANKL on M2 macrophages, we
generated monocyte-derived M2 macro-
phages (Fujimura et al., 2013; Martinez
et al., 2006). This study was approved
by the ethics committee of Tohoku
University Graduate School of
Medicine, Sendai, Japan (2013-1-521),
and all healthy donors and patients
gave written informed consent. Flow
cytometric analysis indicated that all
cells expressed CD163 and arginase 1
(Arg1) (Figure 1a and b), suggesting that
they were M2 macrophages, whereas
only a minor population very weakly
expressed RANK (Figure 1c). However,
when these macrophages were further
cultured with IL-4, most of them strongly
expressed RANK (Figure 1c). We
stimulated these induced RANK+ M2
macrophages with sRANKL and then
examined their mRNA expression of
chemokines, which are known to be
expressed by M2 macrophages
(Mantovani et al., 2002; Hao et al.,
2012). Stimulation with sRANKL aug-
mented the expression of CCL11,
CCL17, and CCL24 mRNA in a dose-
dependent manner, whereas the
expression of CCL18, CCL26, and Arg1
mRNA was not signiﬁcantly affected
(Figure 1d).
To conﬁrm that the observed
increased mRNA expression leads to
protein expression, we used ELISA assay
to examine chemokine protein produc-
tion by M2 macrophages (Figure 1e).
Consistent with the mRNA expression,
the production of CCL17 protein was
signiﬁcantly augmented by sRANKL
stimulation in a dose-dependent man-
ner, whereas the expression of CCL18
protein was not signiﬁcantly altered
(Figure 1e). The production of CCL24
protein was also augmented by sRANKL
stimulation in a dose-dependent man-
ner, although the increases were not
statistically signiﬁcant. In contrast to its
mRNA expression, we could not ﬁnd
any signiﬁcant effects of sRANKL
on the production of IL-10 protein, even
at the highest sRANKL concentration
(Figure 1e). CCL11 protein was not
detected using ELISA assay (data not
shown).
Although the M2 macrophages sti-
mulated by sRANKL signiﬁcantly
augmented the production of CCL17, it
was unclear whether the culture super-
natants of the sRANKL-stimulated M2
macrophages contained T-cell chemo-
tactic factors other than CCL17. We
therefore examined the chemotactic
activity of these culture supernatants
for T cells in the presence or the
absence of anti-CCR4 antibody. The
chemotactic activity of the culture
supernatant of M2 macrophages for
CD4+ T cells signiﬁcantly increased
with sRANKL stimulation in a dose-
dependent manner, in parallel with the
increased production of CCL17
(Figure 2a). This T-cell chemotactic
activity in the culture supernatant of
sRANKL-stimulated M2 macrophages
was signiﬁcantly attenuated by the
anti-CCR4 antibody (Figure 2b). These
ﬁndings suggest that RANK+ M2 macro-
phages stimulated with sRANKL prefer-
entially recruit T cells via CCL17
stimulation of CCR4.
As this in vitro study demonstrated
that RANKL-stimulated M2 macro-
phages produced CCL17, we next exa-
mined whether CD163+ macrophages
in the lesional skin of EMPD expressed
CCL17. When we conducted double
immunoﬂuorescence staining of EMPD
cryosections with a combination of
antibodies against CD163 and CCL17,
most of the CD163+ M2 macrophages
expressed CCL17 (Figure 2c). Notably,
about half of these CD163+ M2 macro-
phages were previously shown to coex-
press RANK (Kambayashi et al., 2015).
Furthermore, when we compared the
mRNA expression of CCL17 and
T-helper cell subset–speciﬁc transcrip-
tion factors between the nonlesional and
lesional skin of EMPD, the expression of
CCL17, GATA3, and Foxp3 mRNA,
but not that of T-bet or RORγt mRNA,
was signiﬁcantly increased in the
lesional skin (Figure 2e). Consistent
with the observed mRNA expression
of the lesional skin, doubleAccepted article preview online 8 June 2015; published online 2 July 2015
Abbreviations: Arg1, arginase 1; DC, dendritic cell; EMPD, extramammary Paget’s disease; RANK,
receptor of activator NF-κB; Treg, regulatory T cell
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Figure 1. Soluble receptor of activator NF-κB ligand (sRANKL) induces the expression of CCL17 mRNA and protein by M2 macrophages. M2 macrophages
were induced from peripheral blood mononuclear cells (PBMCs) from healthy donors, as described in Supplementary Materials and Methods online. The
expression of CD163 and arginase 1 (Arg1) on CD14+ monocytes (a) and M-CSF-induced macrophages (b), and the expression of RANK on cultured M-CSF-
induced macrophages with or without IL-4 (c) were analyzed using ﬂow cytometry. Relative mRNA expression levels of CCL11, CCL17, CCL18, CCL24, CCL26,
IL-10, Arg1, and inducible nitric oxide synthase (iNOS) by nonstimulated (NS) or sRANKL-stimulated M2 macrophages were measured using quantitative reverse
transcriptase–PCR and were calculated using the ΔΔCt method (d). sRANKL induction of the secretion of CCL17, CCL18, CCL24, and IL-10 proteins from M2
macrophages was measured using ELISA assay (e). Data from each donor were obtained from triplicate assays and the mean± s.d. was calculated. *Po0.05 and
**Po0.01 by Student’s t-test; n.s., not signiﬁcant.
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immunoﬂuorescence staining for
CD163 and Foxp3 demonstrated that
Foxp3+ cells surrounded CD163+ M2
macrophages as we previously reported
(Fujimura et al., 2012, 2013; Figure 2d).
In addition, these previous papers sug-
gested that Foxp3+ cells in the lesional
skin of EMPD express CD3, CD4, CD25,
and CD39, suggesting that these Foxp3+
cells are Tregs. These ﬁndings suggested
that M2 macrophages in EMPD might
attract Foxp3+ Tregs by chemotaxis via
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Figure 2. M2 macrophages recruit CCR4-expressing cells in a tumor microenvironment. The chemoattractant activity of the culture supernatant of M2
macrophages for CD4+ T cells without (a) or with (b) an anti-CCR4 antibody was evaluated by using a Neuro Probe AP48 chamber, as described in
Supplementary Materials and Methods. CCL-17 was used as a positive control. Immunoﬂuorescence staining of the lesional skin of extramammary Paget’s disease
(EMPD) for CD163 and CCL17, (c) and for CD163 and Foxp3 (d). Bar = 50 μm. The expression of CCL17, T-bet, Foxp3, GATA3, and RORγt mRNA in the lesional
skin of EMPD was analyzed by quantitative reverse tanscriptase–PCR using the ΔΔCt method (e). The mean± s.e.m. of data from three cases of EMPD is
presented. *Po0.05 by Student’s t-test; n.s., not signiﬁcant.
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CCL17. These results suggest that M2
macrophages stimulated by RANKL/
RANK signaling might recruit Tregs into
the tumor microenvironment of EMPD,
which thereby induces an immunosup-
pressive microenvironment in EMPD.
Gordon and Martinez (2010)
classiﬁed the development of mono-
cytes into mature and fully activated
macrophages into three successive
stages. During the third phase of activa-
tion, macrophages reach a mature
functional phenotype in response to
microbial and opsonic stimuli such as
antibody complexes. In the present
study, macrophages induced by M-CSF
and IL-4 did not produce a substantial
amount of CCL17; however, when
these macrophages were stimulated by
sRANKL, they produced CCL17 in an
sRANKL dose-dependent manner.
These results suggest that sRANKL may
be another stimulus during the third
phase of macrophage activation.
Denosumab, a fully human mono-
clonal antibody for RANKL, is used
clinically to treat metastatic bone
tumors (Azim and Azim, 2013). Our
present study suggests that RANKL
targeting with denosumab can be used
in conjunction with the therapeutic
elimination of primary EMPD to pre-
vent local immunosuppression and
metastatic disease.
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TO THE EDITOR
Higher density of epidermal nerve ﬁbers
has been associated with itch sensitiza-
tion in the periphery, with nerve ﬁber
density being higher in atopic dermatitis
(AD) lesional skin than in normal skin
(Tominaga and Takamori, 2014). Con-
comitantly, the epidermal levels of the
nerve repulsion factor semaphorin 3A
(Sema3A) are lower in AD patients and
AD model NC/Nga mice than in controls
(Tominaga et al., 2008). Sema3A
replacement in AD model NC/Nga mice
normalized hyperinnervation, resulting in
the suppression of itching (Yamaguchi
et al., 2008; Negi et al., 2012).
To defend against pathogens, human
skin contains antimicrobial peptides,
including cathelicidins and β-defensins,
which are induced by inﬂammation
(Schauber and Gallo, 2008; Niyonsaba
et al., 2009). The induction of these
peptides, such as cathelicidin LL-37 and
human β-defensins, produced by epi-
dermal keratinocytes is impaired in
lesional skin in patients with AD,
explaining their frequent infections
(Ong et al., 2002; de Jongh et al.,Accepted article preview online 29 June 2015; published online 16 July 2015
Abbreviations: AD, atopic dermatitis; NHEK, normal human epidermal keratinocyte; P2X7R, P2X7
receptor; Sema3A, semaphorin 3A
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